Cargando…

α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression

BACKGROUND: Studies on chemerin/chemokine-like receptor-1 have mainly focused on adipose and liver with the intestinal tissues largely overlooked. In this study conducted on obese mice, we have explored: 1) CMKLR1 expression in the ileums; 2) CMKLR1 inhibitor α-NETA on body weight and intestinal muc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Canbin, Zheng, Yongping, Chen, Xi, Zhong, Xianyang, Zheng, Xiaobin, Yang, Shuhui, Zheng, Zihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830776/
https://www.ncbi.nlm.nih.gov/pubmed/36624417
http://dx.doi.org/10.1186/s12902-023-01267-9
_version_ 1784867735519363072
author Zheng, Canbin
Zheng, Yongping
Chen, Xi
Zhong, Xianyang
Zheng, Xiaobin
Yang, Shuhui
Zheng, Zihui
author_facet Zheng, Canbin
Zheng, Yongping
Chen, Xi
Zhong, Xianyang
Zheng, Xiaobin
Yang, Shuhui
Zheng, Zihui
author_sort Zheng, Canbin
collection PubMed
description BACKGROUND: Studies on chemerin/chemokine-like receptor-1 have mainly focused on adipose and liver with the intestinal tissues largely overlooked. In this study conducted on obese mice, we have explored: 1) CMKLR1 expression in the ileums; 2) CMKLR1 inhibitor α-NETA on body weight and intestinal mucosa integrity hence the impact on hepatic steatosis and pathway involved. METHODS: Nineteen male C57BL/6 mice were randomly divided into five groups: normal diet group (ND), high-fat diet group (HFD), HFD + α-NETA group (NETA), HFD + PD98059 group (PD) and HFD + α-NETA + PD98059 group (NETA + PD). Mice were fed either with a chow diet or HFD for 12 weeks. At 12(th) week, mice of ND were put on the diet as before; mice of NETA received daily treatments of α-NETA (30 mg/kg) via gavage; mice of PD received daily treatment of PD98059 via tail vein injection; mice of NETA + PD received daily treatment of α-NETA + PD98059, all for another 4 weeks. At the time intervention ended, mice were sacrificed. The body weight, the liver pathologies were assessed. Ileal CMKLR1 mRNA was evaluated by rtPCR; ZO-1, ERK1/2 protein expression of ileal tissues by western blotting; liver TNF-α and serum endotoxin by Elisa. RESULTS: More weight gains in mice of HFD than ND (37.90 ± 3.00 g) vs (24.47 ± 0.50 g), P = 0.002; α-NETA reduced the body weight (33.22 ± 1.90 g) vs (37.90 ± 3.00 g), P = 0.033; and further reduced by NETA + PD98059: (31.20 ± 1.74 g) vs (37.30 ± 4.05 g), P = 0.032. CMKLR1 mRNA expression was up-regulated in ileum in group HFD compared with ND and down-regulated by α-NETA. Steatosis was only alleviated in group PD + NETA with less weight gain. No impact of α-NETA on ileal ZO-1 or pERK with western blotting, and no endotoxin level changes were detected. TNF-α was higher in group HFD than in group ND, while no significant difference between other groups. CONCLUSIONS: CMKLR1 mRNA was up-regulated in the ileum of obese mice and down-regulated by α-NETA along with a body weight control collaborating with ERK inhibitor PD98059. Steatosis was alleviated in a weight dependent way. α-NETA has no influence on intestinal mucosal integrity and no impact on steatohepatitis progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01267-9.
format Online
Article
Text
id pubmed-9830776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98307762023-01-11 α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression Zheng, Canbin Zheng, Yongping Chen, Xi Zhong, Xianyang Zheng, Xiaobin Yang, Shuhui Zheng, Zihui BMC Endocr Disord Research BACKGROUND: Studies on chemerin/chemokine-like receptor-1 have mainly focused on adipose and liver with the intestinal tissues largely overlooked. In this study conducted on obese mice, we have explored: 1) CMKLR1 expression in the ileums; 2) CMKLR1 inhibitor α-NETA on body weight and intestinal mucosa integrity hence the impact on hepatic steatosis and pathway involved. METHODS: Nineteen male C57BL/6 mice were randomly divided into five groups: normal diet group (ND), high-fat diet group (HFD), HFD + α-NETA group (NETA), HFD + PD98059 group (PD) and HFD + α-NETA + PD98059 group (NETA + PD). Mice were fed either with a chow diet or HFD for 12 weeks. At 12(th) week, mice of ND were put on the diet as before; mice of NETA received daily treatments of α-NETA (30 mg/kg) via gavage; mice of PD received daily treatment of PD98059 via tail vein injection; mice of NETA + PD received daily treatment of α-NETA + PD98059, all for another 4 weeks. At the time intervention ended, mice were sacrificed. The body weight, the liver pathologies were assessed. Ileal CMKLR1 mRNA was evaluated by rtPCR; ZO-1, ERK1/2 protein expression of ileal tissues by western blotting; liver TNF-α and serum endotoxin by Elisa. RESULTS: More weight gains in mice of HFD than ND (37.90 ± 3.00 g) vs (24.47 ± 0.50 g), P = 0.002; α-NETA reduced the body weight (33.22 ± 1.90 g) vs (37.90 ± 3.00 g), P = 0.033; and further reduced by NETA + PD98059: (31.20 ± 1.74 g) vs (37.30 ± 4.05 g), P = 0.032. CMKLR1 mRNA expression was up-regulated in ileum in group HFD compared with ND and down-regulated by α-NETA. Steatosis was only alleviated in group PD + NETA with less weight gain. No impact of α-NETA on ileal ZO-1 or pERK with western blotting, and no endotoxin level changes were detected. TNF-α was higher in group HFD than in group ND, while no significant difference between other groups. CONCLUSIONS: CMKLR1 mRNA was up-regulated in the ileum of obese mice and down-regulated by α-NETA along with a body weight control collaborating with ERK inhibitor PD98059. Steatosis was alleviated in a weight dependent way. α-NETA has no influence on intestinal mucosal integrity and no impact on steatohepatitis progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12902-023-01267-9. BioMed Central 2023-01-10 /pmc/articles/PMC9830776/ /pubmed/36624417 http://dx.doi.org/10.1186/s12902-023-01267-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zheng, Canbin
Zheng, Yongping
Chen, Xi
Zhong, Xianyang
Zheng, Xiaobin
Yang, Shuhui
Zheng, Zihui
α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title_full α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title_fullStr α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title_full_unstemmed α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title_short α-NETA down-regulates CMKLR1 mRNA expression in ileum and prevents body weight gains collaborating with ERK inhibitor PD98059 in turn to alleviate hepatic steatosis in HFD-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
title_sort α-neta down-regulates cmklr1 mrna expression in ileum and prevents body weight gains collaborating with erk inhibitor pd98059 in turn to alleviate hepatic steatosis in hfd-induced obese mice but no impact on ileal mucosal integrity and steatohepatitis progression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830776/
https://www.ncbi.nlm.nih.gov/pubmed/36624417
http://dx.doi.org/10.1186/s12902-023-01267-9
work_keys_str_mv AT zhengcanbin anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT zhengyongping anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT chenxi anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT zhongxianyang anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT zhengxiaobin anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT yangshuhui anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression
AT zhengzihui anetadownregulatescmklr1mrnaexpressioninileumandpreventsbodyweightgainscollaboratingwitherkinhibitorpd98059inturntoalleviatehepaticsteatosisinhfdinducedobesemicebutnoimpactonilealmucosalintegrityandsteatohepatitisprogression